BrainStorm Can't Shed Investors' ALS Treatment Trial Claims
By Emilie Ruscoe · September 16, 2025, 7:07 PM EDT
Biopharmaceutical company BrainStorm Cell Therapeutics Inc. must face a proposed investor class alleging it misrepresented feedback from the U.S. Food and Drug Administration regarding clinical trials for an ALS product candidate...
To view the full article, register now.